The Medicaid programs will take about three to six months to conduct a review of Oxbryta before providing widespread reimbursement, but some patients will still be able to begin treatment before that process is concluded, they said. GBT expects that its drug, Oxbryta, will be used in combination with Novartis's drug, Adakveo, for the portion of sickle cell patients who have frequent pain crises, Love told Reuters. Novartis has priced Adakveo between $84,852 and $113,136 per year for most patients. The company's shares closed up about 7%.